Thrombus and antiplatelet therapy in type 2 diabetes mellitus

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Theme Issue
European Vascular Biology Meeting 2011 (Part 2)

Issue: 2012: 108/5 (Nov) pp. 801-1007
Pages: 937-945

Thrombus and antiplatelet therapy in type 2 diabetes mellitus

A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

G. N. Viswanathan (1), S. M. Marshall (1), C. B. Schechter (2), K. Balasubramaniam (1), J. J. Badimon (3), A. G. Zaman (1, 4)

(1) Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; (2) Albert Einstein College of Medicine, New York, New York, USA; (3) Atherothrombosis Research Unit, Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA; (4) Freeman Hospital, Newcastle upon Tyne Hospitals NHS TRust, Newcastle upon Tyne, UK


Acute coronary syndrome, thrombus, Antiplatelet therapy, type 2 diabetes mellitus, stable coronary artery disease


Type 2 diabetes mellitus (T2DM) is associated with higher rates of thrombotic complications in patients with coronary artery disease (CAD) despite optimal medical therapy. Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7–10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS). Secondly, we assessed response to clopidogrel in naive patients with T2DM and stable CAD in a randomised controlled trial. Thrombus area was measured by Badimon chamber and platelet reactivity by VerifyNow®. In T2DM patients presenting with NSTE-ACS, thrombus area was greater compared to non-diabetic patients (mean ± SD, 20,512 ± 12,567 [n=40] vs. 14,769 ± 8,531 [n=40] μm²/mm, p=0.02) Clopidogrel decreased thrombus area among stable CAD patients with T2DM (mean ± SD, Clopidogrel [n=45]: 13,978 ± 5,502 to 11,192 ± 3,764 μm²/mm vs. placebo [n=45]: 13,959 ± 7,038 to 14,201 ± 6,780 μm²/mm, p<0.001, delta values: clopidogrel vs. placebo, mean ± SD, 2,786 ± 4,561 vs. –249 ± 2,478, p<0.0005). Only 44% of patients with CAD and T2DM responded to clopidogrel as per VerifyNow® (cut-off PRUz value of ≥240). Importantly, no correlation was observed between thrombus area and VerifyNow® values (rho 0.08, p=0.49). Thrombus area values were similar among hypo-responders and good responders to clopidogrel (mean thrombus area ± SD: 12,186 ± 4,294 vs. 10,438 ± 3,401; p=0.17). Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy. Thrombus area was significantly reduced in all stable CAD patients independently of their response to clopidogrel therapy.

You may also be interested in...


M. Chatterjee (1), A. Behrendt (1), M. Schmid (1), S. Beck (1), M. Schneider (1), A. Mack (2), I. Müller (1), T. Geisler (1), M. Gawaz (1)

Thromb Haemost 2017 117 2: 311-324

M. Schwarz, B. Saurbier, C. Bode

Hämostaseologie 2008 25 5: 438-447

Francesca Cesari 1, Rossella Marcucci 1, Roberto Caporale 2, Rita Paniccia 1, Eloisa Romano 1, Gian Franco Gensini 3, Rosanna Abbate 1, Anna Maria Gori1

Thromb Haemost 2008 99 5: 930-935